匯鴻集團(600981.SH):匯鴻中鼎擬掛牌轉讓開元醫藥20%股權
格隆匯1月11日丨匯鴻集團(600981.SH)公佈,公司控股子公司江蘇匯鴻國際集團中鼎控股股份有限公司(下稱“匯鴻中鼎”)擬通過公開掛牌方式轉讓所持有的江蘇開元醫藥化工有限公司(下稱“開元醫藥”)20%的股權,轉讓完成後匯鴻中鼎仍將持有開元醫藥25%的股權。
本次股權轉讓完成後,匯鴻中鼎能夠回收資金,將用於補充運營資金或投資其它產業項目,為公司未來新業務佈局提供資金支持。本次交易完成後,公司合併報表範圍將發生變化,開元醫藥將不再列入公司合併報表範圍,上市公司及子公司不存在為開元醫藥提供擔保、委託開元醫藥理財、以及開元醫藥佔用上市公司資金情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.